RC Psychedelics: 1P-LSD, 4-AcO-DMT, 5-MeO-MiPT and Other Novel Tryptamines/Lysergamides

RC Psychedelics

Quick answer

The psychedelic RC market includes several chemically distinct families:

• lysergamides such as 1P-LSD and related LSD analogues;
• 4-substituted tryptamines such as 4-AcO-DMT;
• 5-methoxy tryptamines such as 5-MeO-MiPT;
• phenethylamine-like psychedelics and NBOMe/NBOH compounds.

These should not be collapsed into a single “psychedelics are physiologically safe” category.

1P-LSD is unusually well characterized for an RC

A small controlled human pharmacokinetic study found that 1P-LSD is rapidly converted to LSD and that the subjective time course was consistent with that prodrug relationship.

That does not make unregulated blotter identity guaranteed, but it gives 1P-LSD a stronger human pharmacology anchor than many other RC psychedelics.

4-AcO-DMT has a different evidence problem

4-AcO-DMT, also called psilacetin or O-acetylpsilocin, is one of the most commonly discussed novel tryptamines.

Analytical and metabolic studies exist, and animal work supports psychedelic-like serotonergic activity.

Direct controlled human research is still sparse.

That means confident claims about dose equivalence to psilocybin or psilocin are much less secure than internet familiarity may suggest.

5-MeO-MiPT has documented toxicity signals

5-MeO-MiPT (“Moxy”) has been involved in human poisoning reports.

Preclinical research documents motor, sensorimotor, thermoregulatory and cardiorespiratory effects, reinforcing that this is not simply a low-risk “functional psychedelic.”

The NBOMe lesson

The broader psychedelic RC market has already shown why identity matters.

Highly potent NBOMe-family compounds have historically been misrepresented as LSD and have been linked to severe toxicity and deaths.

A blotter or powder sold as a familiar psychedelic does not prove identity.

Interactions matter

Serotonergic drugs can become more difficult to interpret when mixed with:

• MAO inhibitors;
• serotonergic stimulants;
• MDMA-like entactogens;
• certain antidepressants;
• lithium;
• other psychoactive drugs.

The specific risk depends on the compound and interaction.

High-priority profiles

• 1P-LSD
• 4-AcO-DMT / Psilacetin
• 4-HO-MET / Metocin
• 5-MeO-MiPT / Moxy
• NBOMe & NBOH psychedelics
• 25I-NBOMe
• 25E-NBOH

4-AcO-MET, 1cP-LSD and 1V-LSD remain reasonable future targets if the available evidence supports a page that adds more than market anecdotes.

Additional individual profiles

• 1cP-LSD
• AL-LAD
• 2C-B-FLY

Bottom line

The RC psychedelic category contains everything from compounds with direct human PK evidence to drugs known mainly from animal, analytical, or poisoning studies.

The safest evidence standard is to treat each molecule separately rather than assuming that “psychedelic” means a uniform risk profile.

What confirmed cases actually contribute

When RC Psychedelics appears in an analytically confirmed poisoning or forensic report, the finding proves that the drug reached the real-world market and can be associated with clinically important effects. It does not automatically prove sole causation if other substances were present. This distinction matters because many NPS cases involve co-use, uncertain timing, or unverified product concentration. The strongest conclusions are the ones that remain accurate after those confounders are acknowledged.

Product-market uncertainty changes the evidence question

With RC Psychedelics, the first scientific question in a real-world exposure is often not “what is the ideal effect profile?” but “was the material actually RC Psychedelics?” NPS markets can contain substitutions, mixtures, and variable concentrations. A reagent result or partial drug-checking panel can narrow possibilities but may not identify every active ingredient.

That is why this site treats chemistry verification, clinical effects, and mechanism as separate layers instead of using a subjective experience report to infer all three.

When uncertainty becomes a clinical problem

The point of documenting RC Psychedelics is not to teach someone how to optimize an exposure. It is to help recognize when an unexpected reaction is outside the range that should be managed casually. Seizure, dangerous overheating, collapse, severe cardiovascular symptoms, persistent confusion, or inability to stay awake are reasons for medical evaluation.

If multiple psychoactive drugs were involved, that information matters to clinicians even when the exact contribution of each substance cannot be reconstructed.

Why the evidence grade stays conservative

Availability can expand much faster than formal research. RC Psychedelics may therefore accumulate hundreds of internet reports before there is a meaningful clinical dataset. Volume of anecdotes is not the same thing as replication under known exposure conditions.

This page will change as better evidence appears. For now, analytical confirmation and well-documented human cases outrank informal potency rankings, and missing data remain explicitly missing.